The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents

Li-jun Shen¹,², Hui-wei Sun³, Yan-yao Chai³, Qi-yu Jiang³, Jian Zhang⁴, Wen-ming Li⁵* and Shao-jie Xin¹,⁶*

¹ Medical School of Chinese People’s Liberation Army (PLA), Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China, ² Division 8, Department of Hepatology, Senior Department of Hepatology, The Fifth Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China, ³ Senior Department of Infectious Disease, Institute of Infectious Disease, The Fifth Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China, ⁴ Department of Patient Management, The Fifth Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China, ⁵ Department of Emergency Medicine, Handan Central Hospital, Handan, Hebei Province, China, ⁶ Division 6, Department of Hepatology, Senior Department of Hepatology, The Fifth Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China

NF-κB (nuclear factor κB) is a regulator of hepatocellular cancer (HCC)-related inflammation and enhances HCC cells’ resistance to antitumor therapies by promoting cell survival and anti-apoptosis processes. In the present work, we demonstrate that A20, a dominant-negative regulator of NF-κB, forms a complex with HSP90 (heat-shock protein 90) and causes the disassociation of the A20/HSP90 complex via downregulation of HSP90. This process restores the antitumor activation of A20. In clinical specimens, the expression level of A20 did not relate with the outcome in patients receiving sorafenib; however, high levels of HSP90 were associated with poor outcomes in these patients. A20 interacted with and formed complexes with HSP90. Knockdown of HSP90 and treatment with an HSP90 inhibitor disassociated the A20/HSP90 complex. Overexpression of A20 alone did not affect HCC cells. Downregulation of HSP90 combined with A20 overexpression restored the effect of A20. Overexpression of A20 repressed the expression of pro-survival and anti-apoptosis-related factors and enhanced HCC cells’ sensitivity to sorafenib. These results suggest that interactions with HSP90 could be potential mechanisms of A20 inactivation and disassociation of the A20/HSP90 complex and could serve as a novel strategy for HCC treatment.

Keywords: A20, heat-shock protein 90, advanced hepatocellular carcinoma, molecular targeted agents, drug resistance
INTRODUCTION

Hepatocellular carcinoma (HCC) is a significant challenge to China’s public health system because of the high infection rates with hepatitis virus (1). These patients are at significant risk of progressing to HCC, and most patients are in the advanced stage of disease at the initial diagnosis (2, 3). Unfortunately, outcomes for patients with advanced HCC are unsatisfactory because of resistance to radiotherapy and multi-drug resistance (4–6). For these reasons, molecularly targeted agents are ever more critical for treating advanced HCC (7, 8). Although targeted molecular drugs represented by sorafenib in several clinical trials were shown to prolong survival and improve quality of life, molecular targeted therapy is also associated with many problems: (1) sorafenib treatment produces drug resistance and severe side effects (9); (2) in addition to sorafenib, new molecular targeted drugs such as lenvatinib, regorafenib, and cabozantinib have been marketed (10–12). Although these drugs are considered superior to sorafenib, they have similar structural features and the same chemical structure as sorafenib (1-(4-(pyridin-4-yl)oxy)phenyl) urea). For these reasons, lenvatinib, regorafenib, and cabozantinib may not be able to overcome all the insufficiencies of sorafenib. Therefore, it has become essential to research and explore the resistance mechanism of HCC cells to molecularly targeted drugs to develop new and more effective treatment strategies to achieve the same and better anti-tumor effects with smaller doses of drugs.

Several lines of evidence suggest that NF-κB is activated by upstream signals pathways to enhance anti-apoptosis and pro-survival of cancerous cells by mediating expression genes such as Bcl-2, cIAPs (cellular inhibitor of apoptosis), and survivin (13, 14). Kang et al. found that blocking the activation of the Notch-1/NF-κB pathway using small molecular inhibitors enhanced the sensitivity of cancer cells to ionizing radiation (IR) (15). This evidence suggests that inhibition of NF-κB activation may enhance HCC cells’ sensitivity to antitumor therapies, including molecular targeting agents (16, 17). The master suppressor of NF-κB A20 is tumor necrosis factor-alpha-induced protein 3 (A20) that is thought to be a tumor suppressor of NF-κB (5). The downregulation of A20 enhanced HCC cells’ sensitivity to radiotherapies via suppressing the expression of NF-κB downstream pro-survival and anti-apoptosis-related factors (6). In the present work, unexpectedly, we were first to show that overexpression and knockdown of A20 did not affect the expression of NF-κB downstream pro-survival and anti-apoptosis-related factors in HCC cells. Mechanistically, A20 formed a complex with HSP90, and the disassociation of the A20/HSP90 complex via downregulation of HSP90 restored the effect of A20 enhancing the sensitivity of HCC cells to sorafenib.

MATERIAL AND METHODS

Clinical Specimens and Ethics Statement
The clinical specimens (52 paired HCC and non-tumor tissues) used in the present work were described in our previous publications (21). The ethics committee approved the use of human-related materials from the Fifth Medical Center, General Hospital of the Chinese PLA. We obtained written consent from the patients.

Cell Lines and Agents
The hepatic cell lines, including L-02 (hepatic non-tumor cell line) and HCC cell lines (MHCC97-H, MHCC97-L, HepG2, Huh-7, SMMC-7721, and BEL7402), were described in our previous publications (22, 23). The cells were cultured in DMEM with 10% FBS. The molecular targeting agents, sorafenib (Cat. No.: S7397), regorafenib (Cat. No.: S1178), lenvatinib (Cat. No.: S1164), and cabozantinib (Cat. No.: S1119) were purchased from Selleck Corporation, Houston, Texas, USA. The inhibitor of HSP90 BIIB021 was purchased from the Selleck Corporation. The formulations of these agents used in the cellular and animal experiments were prepared by the methods described by Ma et al., Wang et al., and Zhou et al. (24–26). The siRNA (sequence: GCAGCAAAGUGGCGU AUUA) (27) of HSP90 and the full-length sequence of A20 were cloned and prepared as lentivirus particles.

qPCR and Survival Analysis
Total RNA samples were extracted using a PARISTM Kit (Thermo Fisher Scientific, Waltham, MA, USA) from HCC cells and tumor tissues. They were reverse transcribed using a Multiscribe™ Reverse Transcriptase (Thermo Fisher Scientific) agent following the manufacturer’s instructions. The quantitative polymerase chain reaction (qPCR) was performed following the manufacturer’s instructions and previously described methods (28, 29). mRNA levels of β-actin (loading control) were measured as the loading control. Primers used in qPCR experiments are listed: (1) HSP90 (HS90PA1A): Forward Sequence, 5’-TCTGCCCTCTGTGTA TGAGATGGG-3’; Reverse Sequence, 5’-CTTCCACAAAGGCGTAGTTAGC-3’; (2) A20 (TNFAIP3): Forward Sequence, 5’-CTCAACTGGGTTGC GAGAATGCC-3’; Reverse Sequence, 5’-TTCCTTGA GGTGTCGTAACAGC-3’; (3) BCL2: Forward Sequence, 5’-ATGGCCCTGT GGATGACTGAGT-3’; Reverse Sequence, 5’-CGGATGT CCACGT-3’; (4) Survivin (BIRC5) Forward Sequence, 5’-CCACTGAGACGAGCCAGACTT-3’; Reverse Sequence, 5’-GTATTAGCGGCGTAAGCCAC-3’; (5) β-Actin (ACTB) Forward Sequence, 5’-CACCATTGGGAT ATGAGCGGTTCC-3’; Reverse Sequence, 5’-AGGCTTTTG CGGATGTCACGC-3’; (6) HSP90 Forward Sequence, 5’-CGGATGTCCACGT-3’; Reverse Sequence, 5’-CGGATGTCCACGT-3’

The Immunoprecipitation and Western Blot
MHCC97-H cells were cultured and harvested for immunoprecipitation according to our previous publications (30–32). Briefly, the MHCC97-H cells were harvested for immunoprecipitation and western blotting. The HSP90/A20 complexes were separated using mouse anti-human HSP90
expression levels of pro-survival and anti-apoptosis-related vectors. The cells were harvested for western blotting, and siA20; MHCC97-L cells were transfected with control and A20 vectors. The cells were harvested for western blotting, and the expression levels of pro-survival and anti-apoptosis-related factors were examined using antibodies.

**Cell Survival Analysis**

Cell survival analysis was performed to determine the antitumor effects of molecular targeting agents on HCC cells. HCC cells were cultured using DMEM with 10% FBS and treated with indicated concentrations of molecular targeting agents. For the MTT experiments, HCC cells were harvested and seeded into 96-well plates (about 8000 cells per well). Then, cells were treated with the indicated concentration of the molecular targeting agents (10 μmol/L, 3 μmol/L, 1 μmol/L, 0.3 μmol/L, 0.1 μmol/L, and 0.03 μmol/L) for 48 h. After treatment, cells were treated with 50 mmol/L MTT for 4 h, and the cells were harvested. We determined cell numbers using the optical density (OD) values at 490 nm. The inhibitor rates of molecular targeting agents on HCC cells were calculated according to the OD values at 490 nm, and the IC50 values were calculated based on the inhibitory rates (34, 35). For colony formation, the HCC cells were transfected with plasmids, treated with agents, and seeded onto 6-well plates (2000 cells per well). After 3-4 weeks' growth, HCC cells formed colonies. We used absolute ethanol to fix the colonies formed by HCC cells in 6-well plates, stained the colonies with 0.5% W/V crystal violet staining solution, and obtained pictures to quantitatively analyze the images according to published methods (36, 37).

**The In Vivo Tumor Model and Ethics Statement**

The in vivo growth of HCC cells was measured using a nude mice model (38, 39). All animal experiments were approved by the Institutional Animal Care and Use Committee of the Chinese PLA General Hospital, China. All animal experiments (n = 10 for each group and animals were randomly divided into the groups) were performed according to the UK Animals (Scientific Procedures Act, 1986) and the associated guidelines. For the subcutaneous tumor model, MHCC97-H cells were injected into the nude mice's subcutaneous position to form tumor tissues. Mice then received sorafenib and BIIB021 via oral administration following the methods described previously (40). The tumor tissues were harvested, and the tumor volumes and weights were measured (41). Expression levels of A20, HSP90, survivin, and BCL-2 in tumor tissues were measured using qPCR.

**The Intra-Hepatic Tumor Model**

The in vivo growth of HCC cells was further examined using the intra-hepatic tumor model (40). MHCC97-H cells were cultured and transplanted into the nude mice’s livers as described (40). Mice were treated with sorafenib and BIIB021 via oral administration as described (40). The intrahepatic growth of MHCC97-H cells in nude mice was measured by (1) microPET; (2) radio-activation of the liver to blood; and (3) the quantitative analysis of the images of livers with nodules (40). We used microdissection and other methods to separate liver nodules. The expression levels of A20, HSP90, survivin, and BCL-2 were measured using qPCR (42).

**Statistical Analysis**

In the presence work, the biological and technical replicates have been carried out for all experiments and the results were from triple repeats with similar results. All statistical significance analyses were performed using SPSS 9.0 statistical software (IBM Corporation, Armonk, NY, USA). The IC50 values were calculated using Origin software (Origin 6.1; OriginLab Corporation, Northampton, MA, USA). Statistical significance was analyzed using Bonferroni correction with two-way ANOVA, and paired samples were tested using the paired-sample t-test (SPSS Statistical Software v16.0; SPSS Inc., Chicago, IL, USA).

**RESULTS**

**Overexpression and Knockdown of A20 Did Not Affect HCC Cells**

To examine the roles of A20 in HCC, expression levels of A20 in clinical specimens were measured. As shown in Figure 1A, expression levels of A20 were much higher in HCC tissues than in non-tumor tissues. In hepatic cell lines, expression levels of A20 were much lower in L-02, a non-tumor hepatic cells line, than in HCC cells (Figure 1B). Among the HCC cells, the MHCC97-L cells had the lowest expression levels of A20, and the MHCC97-H cells had the highest expression levels (Figure 1B). Therefore, MHCC97-H cells were used to knockdown A20, whereas MHCC97-L cells were used to overexpress A20 in subsequent experiments.

The correlation of A20 expression with HCC patients' outcomes was further examined. In HCC tissue specimens, according to the median of A20 mRNA expression, patients were divided into two groups: the A20 high expression group and the A20 low expression group (Figure 1C). The survival analysis of the two groups showed that there was no correlation between expression levels of A20 and outcome patients receiving sorafenib (Figures 1D, E and Table 1), and there was no significant difference in the survival time between the two groups (Figures 1D, E and Table 1). Therefore, A20 would be inactive in HCC cells.

Next, the effect of A20 overexpression and A20 knockdown on HCC cells' sensitivity to sorafenib was examined. As shown in Figures 1F–H and Table 2, overexpression of A20 did not affect the expression of pro-survival and anti-apoptosis-related factors (Figure 1F and Table 2). It did not affect the sensitivity of MHCC97-L cells to sorafenib and other agents (Figures 1G, H and Table 2).
Similar results were obtained via knockdown of A20 in MHCC97-H cells (Figures 1I–K and Table 3). A20 is thought to be a tumor suppressor; however, the results were inconsistent; therefore, we needed to explore the mechanism of A20 in HCC further.

**A20 Formed a Complex With HSP90 and the Complex Could Be Disassociate via Downregulation of HSP90**

Next, the mechanism of A20’s effect in HCC cells was examined. As shown in Figure 2A, HSP90 interacted with A20 in
MHCC97-H cells. Transfection with HSP90’s siRNA and treatment with the HSP90 inhibitor BIIB021 inhibited the interaction between HSP90 and A20. High levels of HSP90 A20 expression with outcome was further examined. Then, the association of HSP90 with HCC patients’ prognosis was also examined. In HCC tissue specimens, according to the median of HSP90 mRNA expression, patients were divided into two groups: the HSP90 high expression group and the HSP90 low expression group (Figure 2B). The survival analysis of the two groups was examined. The OS (overall survival) or the TTP (time to progress) of patients with high-level of HSP90 (HSP90-high group) was much shorter than patients with high-level of HSP90 (HSP90-high group) (Figures 2C, D and Table 4). Therefore, Whether A20 in the HSP90-A20 complex is active may depend on the state of HSP90.

**Downregulation of HSP90 via Its siRNA or Small Molecular Inhibitor Enhances the In Vitro Sensitivity of HCC Cells to Macular Targeted Agents**

The effect of the disassociation of the A20/HSP90 complex on HCC cells’ sensitivity to sorafenib was examined. As shown in Figures 2E–G and Table 3, in MHCC97-H cells with high level of A20, knockdown of HSP90 via its siRNA or small molecular did not affect the expression of A20 but decreased the expression of pro-survival and anti-apoptosis-related factors (Figures 2E–G and Table 3) and enhanced the sensitivity of MHCC97-H cells to molecular targeting agents. Moreover, in MHCC97-L cells with low level of endogenous A20, overexpression of A20 alone did not affect the sensitivity of MHCC97-L cells to sorafenib and other agents or the expression of pro-survival or anti-apoptosis related factors (Figures 2H–J and Table 2), however, overexpression of A20 combined with HSP90 inhibitor not only enhanced the sensitivity of MHCC97-L cells to sorafenib and other agents but also inhibited the expression of pro-survival or anti-apoptosis related factors (Figures 2H–J and Table 2). The results from cellular survival examination (the MTT experiments) was confirmed by colony formation experiments (Figures 2K–N). Therefore, downregulation of HSP90 via its siRNA or small molecular inhibitor enhances the in vitro sensitivity of HCC cells to macular targeted agents.

**Knockdown of HSP90 Enhanced the In Vivo Antitumor Activity of Sorafenib and Repressed the Pro-Survival and Anti-Apoptosis-Related Factors in Subcutaneous Tumors**

To further examine the effect of HSP90, the subcutaneous tumor model was used. As shown in Figures 3, 4, MHCC97-H cells formed subcutaneous tumors. Oral administration of 0.5 mg/kg sorafenib did not significantly affect the subcutaneous growth of HCC cells in nude mice. Knockdown of HSP90 via its siRNA and oral administration of HSP90 enhanced the sensitivity of HCC cells to sorafenib. It repressed the expression of NF-κB downstream pro-survival and anti-apoptosis-related factors (Figures 3 and 4). These findings suggest that the inhibitory effect of A20 was rescued in the presence of HSP90 siRNA and HSP90 inhibitor.

**Knockdown of HSP90 Enhanced the In Vivo Antitumor Activity of Sorafenib and Repressed the Pro-Survival and Anti-Apoptosis-Related Factors in the Intrahepatic Tumor Model**

The previous results focused on the subcutaneous growth of HCC cells. The in vivo growth of HCC cells was further examined using an intrahepatic tumor model. As shown in Figure 5, MHCC97-H cells could form the intrahepatic lesions or nodules in nude mice’s liver organs and the intrahepatic growth of MHCC97-H cells were measured by the microPET or the images of liver organs. Treatment of 1mg/kg Sorafenib could inhibit the intrahepatic growth of MHCC97-H cells. Treatment of BIIB021, the small molecular targeting agents Control A20 A20+siHSP90 A20+BIIB021 /IC50 values (μmol/L) Sorafenib 1.05 ± 0.25 0.96 ± 0.15 0.15 ± 0.04 0.24 ± 0.11 Regorafenib 0.97 ± 0.08 1.15 ± 0.54 0.10 ± 0.06 0.51 ± 0.22 Lenvatinib 1.21 ± 0.54 1.31 ± 0.39 0.24 ± 0.07 0.13 ± 0.02 Cabozantinib 1.01 ± 0.41 0.93 ± 0.47 0.16 ± 0.13 0.23 ± 0.09

**TABLE 1 |** The association between A20 and the prognosis of HCC patients received Sorafenib.

| A20 mRNA expression | P values |  |
|---------------------|----------|---|
| High (n = 26)       | Low (n = 26) |  |
| TTP                 | 10       | 10 | 0.85 |
| 6.9-13.1 (M)        | 8.6-11.4 (M) |  |
| OS                  | 11       | 10 | 0.877 |
| 7.0-15.0 (M)        | 5.7-14.3 (M) |  |

M, month; TTP, time to progress; OS, overall survival.

**TABLE 2 |** The effect of HSP90 knock down on the sensitivity of MHCC97-H cells to molecular targeted agents.

| Agents     | Control | siHSP90 | BIIB021 |
|------------|---------|---------|---------|
| IC50 values (μmol/L) |         |         |         |
| Sorafenib | 0.56 ± 0.11 | 0.15 ± 0.05 | 0.18 ± 0.06 |
| Regorafenib | 0.89 ± 0.68 | 0.06 ± 0.03 | 0.15 ± 0.03 |
| Lenvatinib | 0.42 ± 0.10 | 0.08 ± 0.04 | 0.05 ± 0.01 |
| Cabozantinib | 0.39 ± 0.21 | 0.22 ± 0.01 | 0.19 ± 0.14 |

**TABLE 3 |** The effect of A20 or HSP90 knockdown on the sensitivity of MHCC97-L cells to molecular targeted agents.

| Agents     | Control | A20 | A20+siHSP90 | A20+BIIB021 |
|------------|---------|-----|------------|------------|
| IC50 values (μmol/L) |         |     |            |            |
| Sorafenib | 1.05 ± 0.25 | 0.96 ± 0.15 | 0.15 ± 0.04 | 0.24 ± 0.11 |
| Regorafenib | 0.97 ± 0.08 | 1.15 ± 0.54 | 0.10 ± 0.06 | 0.51 ± 0.22 |
| Lenvatinib | 1.21 ± 0.54 | 1.31 ± 0.39 | 0.24 ± 0.07 | 0.13 ± 0.02 |
| Cabozantinib | 1.01 ± 0.41 | 0.93 ± 0.47 | 0.16 ± 0.13 | 0.23 ± 0.09 |
molecular inhibitor of HSP90, enhanced the antitumor effect of Sorafenib on MHCC97-H’s intrahepatic growth. The results were shown as the images of liver organs with nodules (Figure 5A) or the quantitative results (Figures 5B, C). The effect of Sorafenib or BIIB021 on MHCC97-H cells was confirmed by the qPCR examining the pro-survival or anti-apoptosis related factors in lesions tissues (D-F). Therefore, the Knockdown of HSP90 enhanced the in vivo antitumor activity of sorafenib and...
repressed the pro-survival and anti-apoptosis-related factors in the intrahepatic tumor model.

**DISCUSSION**

Although many advantages have been achieved, the treatment of advanced HCC faces considerable obstacles (43). First, the one-third, two-thirds, and whole liver can only accept 90, 47, and 31 Gy doses of IR, respectively; however, these doses of IR are only partial doses of the HCC-control dose. Radio-resistance limits the application of radiotherapy for HCC treatment (6). Moreover, local therapeutic strategies, such as radiofrequency ablation, transhepatic artery chemoembolization, and cryoablation are invasive therapies for advanced HCC; the associated recurrence rates after local treatment cannot be ignored (44, 45). Therefore, it critical to identify targeted molecular therapies to achieve safer and more effective strategies. Several studies provided molecular clues that the pro-survival and anti-apoptotic response to NF-κB would be potential targets (46, 47). Based on the evidence that zinc finger protein A20 functioned as a negative regulator of NF-κB, overexpression of A20 and enhancing the activation of A20 could enhance HCC cells’ sensitivity to molecularly targeted agents via restricting the activation of the NF-κB pathway (6). However, the function of A20 in HCC has been rarely reported, and there are no universal roles regarding A20’s function. Liu et al. suggested that A20 was a tumor suppressor in HCC that

| HSP90 mRNA expression | P values |
|-----------------------|---------|
| High (n = 26)         | Low (n = 26) |
| TTP                   |         |
| 8                     | 12       | 0.01 |
| 6.0-10.0 (M)          | 7.2-16.8 (M) |
| OS                    |         |
| 11                    | 16       | 0.02 |
| 7.7-14.3 (M)          | 9.4-22.6 (M) |

*M, month; TTP, time to progress; OS, overall survival.*
enhanced HCC cells’ sensitivity to $^{60}$Co-$\gamma$ IR (6). Chen et al. found that overexpression of A20 repressed the proliferation and metastasis of HCC cells via inhibiting the expression of Twist1 with higher expression levels in HCC tissues and cell lines than in non-tumor control (48). Other investigators reported opposite trends. Dong et al., Wang et al. and Wang et al. showed that A20 was a positive regulator of HCC cell survival and proliferation (49–51), and knockdown of A20 attenuated the proliferation and metastasis of HCC cells and protected the cells from injury induced by TNF$\alpha$ treatment (49–51). In the present study, the expression of A20 in HCC tissues was higher than in non-tumor tissues, but A20 itself may not affect the activity of the pro-survival/anti-apoptosis related downstream factors of NF-$\kappa$B (Figure 6). The expression of pro-survival and anti-apoptotic factors in downstream cells of NF-$\kappa$B suggests that A20 may lose activity in HCC cells.

Furthermore, we found that HSP90 and A20 form a complex in HCC cells to inhibit the activity of A20. The use of HSP90 siRNA and HSP90 small molecule inhibitors can inhibit HSP90 and A20 complexes’ formation and finally release A20 from the complex. Restore activity, and finally down-regulate the expression level of NF-$\kappa$B downstream related factors. The expression of A20 in HCC tissues does not correlate with the prognosis of patients, while HSP90 is highly expressed in HCC tissues, and the expression level of HSP90 is negatively correlated with the prognosis of patients.

The HSP90 (heat shock proteins 90) is present at low levels under normal conditions; however, these levels are significantly elevated in the presence and injury in response to cellular stresses (52). Previously, HSP90 was considered an essential molecular chaperone that participates in physical processes, including protein homeostasis, cellular apoptosis, migration/invasion, and cellular signaling transduction (53). Studies have provided clues that HSPs functions as an essential regulator of HCC and overexpression of HSP90 (54). HSP90 is often associated with poor outcome and antitumor treatment resistance (55). Knockdown of HSP90 activation using small molecular inhibitors such as 5-aryl-3-thiophen-2-yl-1H-pyrazoles and AUY922 (luminespib) attenuated the proliferation of HCC cells (56–58). Mechanically, the oncogenic effect of HSP90 is often associated with some oncogene or pro-oncogene, e.g., c-MYC (59). Our findings suggest that HSP90 interacts with A20, while A20 in the A20-HSP90 complex may not be active. Treating cells with inhibitors of HSP90 induces the dissociation of the HSP90-A20 complex, and A20 was released. The activity of A20 enhancing the sensitivity of HCC cells to molecularly targeted drugs was rescued. The results of this study expand our understanding of HSP90 regulation of HCC cells.

FIGURE 4 | Knockdown of HSP90 in MHCC97-H cells via BIIB021 enhances the antitumor effect of Sorafenib on the subcutaneous growth of MHCC97-H cells in nude mice. MHCC97-H cells were injected into the nude mice to form the subcutaneous tumors. Mice were received Sorafenib or BIIB021 via oral administration. The results were shown as the images of tumor tissues (A), tumor volumes (B), tumor weights (C) or the expression level of pro-survival or anti-apoptosis related factors in the tumor tissues (D–G). *P < 0.05.
It is worth mentioning that the cellular stress response mechanism has attracted considerable attention (60). For example, the cellular injury response mechanism represented by Notch is closely related to the proliferation, metastasis, and invasion of malignant tumor cells such as HCC, and it induced resistance to anti-tumor treatments (61, 62). Cytotoxic chemotherapy drugs, molecularly targeted drugs, IR, and thermal ablation can be used as damage/stress factors to cells to induce activation of the Notch pathway (63, 64). The activated Notch pathway promotes survival by inducing pro-survival and anti-apoptosis-related factors, protecting cells, and ultimately inducing cells' resistance to anti-tumor treatments (65, 66). The stress response is the primary function of HSP90 (67, 68).

The occurrence and progression of HCC are closely related to inflammation (69). Under repeated stimulation of liver injury induced by the hepatitis B virus, liver cells eventually become cancerous (69, 70). HSP90 is closely related to the hepatitis B virus. The high expression of HSP 90 in HCC resulted from the induction of stress factors such as inflammation and liver damage during the occurrence and progression of HCC (71). A20 is thought to be a tumor suppressor; it was initially discovered as an inhibitor of inflammatory responses and other stress factors (72). Taken together, these findings suggest that high expression levels of A20 in HCC may represent the body's protective effect against liver damage and stress responses. However, high expression levels of HSP90 in HCC cells eventually cause A20...
inactivation by forming a complex with HSP90. This study’s results provide a possible mechanism for the inconsistency of current A20-related research: A20 can be used as a tumor suppressor; however, A20’s role depends on whether HSP90 is aberrantly expressed. The cellular stress response process is closely related to the tumor tissue microenvironment, and the tumor tissue microenvironment is closely related to the epithelial-mesenchymal transition of malignant tumor cells (73–76). Future studies will focus on the relationship between HSP90 and epithelial-mesenchymal transition.

CONCLUSION

A20 and HSP90 form a complex in HCC cells, and A20 loses its activity. The HSP90-A20 complex dissociated and released A20, which rescues the activity of A20 and enhances the sensitivity of HCC cells to molecularly targeted agents.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the animal ethic committee of the Fifth Medical Center of the PLA General Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the animal ethic committee of the fifth medical center, the PLA General Hospital of China.

REFERENCES

1. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, et al. Polaris Observatory Collaborators Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study. Lancet Gastroenterol Hepatol (2018) 3(6):383–403. doi: 10.1016/S2468-1253(18)30056-6
2. Llovet JM, Montal R, Sia D, Finn RS. Molecular Therapies and Precision Medicine for Hepatocellular Carcinoma. Nat Rev Clin Oncol (2018) 15(10):599–616. doi: 10.1038/s41571-018-0073-4
3. Forner A, Reig M, Bruix J. Hepatocellular Carcinoma. Lancet (2018) 391(10127):1301–14. doi: 10.1016/S0140-6736(18)30010-2
4. Kim DW, Talati C, Kim R. Hepatocellular Carcinoma (HCC): Beyond Sorafenib-Chemotherapy. J Gastrointest Oncol (2017) 8(2):256–65. doi: 10.21037/jgo.2016.09.07
5. Gao Y, Fan X, Li N, Du C, Yang B, Qin W, et al. CCL22 Signaling Contributes to Sorafenib Resistance in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Pharmacol Res (2020) 157:104800. doi: 10.1016/j.phrs.2020.104800
6. Liu R, Zhao D, Zhang X, Han S, Yang Y, Ma J, et al. A20 Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells to 60Co-γ Ionizing Radiation. Oncotarget (2017) 8(54):93103–16. doi: 10.18632/oncotarget.21860
7. Roskoski R Jr. Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors. Pharmacol Res (2019) 144:19–50. doi: 10.1016/j.phrs.2019.03.006
8. Roskoski R Jr. Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2020 Update. Pharmacol Res (2020) 152:104609. doi: 10.1016/j.phrs.2019.104609
9. He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, et al. New Frontiers Against Sorafenib Resistance in Renal Cell Carcinoma: From Molecular Mechanisms to Predictive Biomarkers. Pharmacol Res (2021) 170:105732. doi: 10.1016/j.phrs.2021.105732
10. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. Lancet (2018) 391(10126):1163–73. doi: 10.1016/S0140-6736(18)30207-1
11. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet (2017) 389(10064):56–66. doi: 10.1016/S0140-6736(16)32453-9
12. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in Patients With Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med (2018) 379(1):54–63. doi: 10.1056/NEJMoa1717002
13. Kunze B, Wein F, Fang HY, Anand A, Baumeister T, Strangmann J, et al. Notch Signaling Mediates Differentiation in Barrett’s Esophagus and Promotes Progression to Adenocarcinoma. Gastroenterology (2020) 159(2):575–90. doi: 10.1053/j.gastro.2020.04.033
14. Anchi P, Swamy V, Godugu C. Nimibolide Exerts Protective Effects in Complete Freund’s Adjuvant Induced Inflammatory Arthritis via Abrogation of STAT-3/NF-Kappab/Notch-1 Signaling. Life Sci (2021) 266:118911. doi: 10.1016/j.lfs.2020.118911
15. Kang J, Kim E, Kim W, Seong KM, Youn H, Kim JW, et al. Ramumbin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-Mediated Suppression of Notch-1 Expression.
in Non-Small Cell Lung Cancer Cell Lines. *J Biol Chem* (2013) 288(38):27343–57. doi: 10.1074/jbc.M113.490482

16. Corman W, D’Ambrosio S, Meena A. Prospects of Tangeretin as a Modulator of Cancer Targets/Pathways. *Pharmacol Res* (2020) 161:105202. doi: 10.1016/j.phrs.2020.105202

17. Farooqi AA, Butt G, El-Zahaby SA, Attar R, Sabitaliyevich U, Jovic JJ, et al. Luteolin Mediated Targeting of Protein Network and microRNAs in Different Cancers: Focus on JAK-STAT, NOTCH, mTOR and TRAIL-Mediated Signaling Pathways. *Pharmacol Res* (2020) 160:105188. doi: 10.1016/j.phrs.2020.105188

18. Feng Y, Zhang Y, Cai S, Liu R, Lu M, Li T, et al. A20 Targets PKR and Glycogen to Inhibit the Progression of Hepatocellular Carcinoma. *Cell Death Dis* (2020) 11(2):89. doi: 10.1038/s41419-020-2278-6

19. Ma J, Wang H, Guo S, Yi X, Zhao T, Liu Y, et al. A20 Promotes Melanoma Progression via the Activation of Akt Pathway. *Cell Death Dis* (2020) 11(9):794. doi: 10.1038/s41419-020-03001-y

20. Lu H, Betancur A, Chen M, Ter Meulen JH. Toll-Like Receptor 4 Expression With SyntheticTLR4 Agonist Glucopyranosyl Lipid A. *Front Oncol* (2020) 10:1348. doi: 10.3389/fonc.2020.01438

21. Feng F, Jiang Q, Cao S, Cao Y, Li R, Shen L, et al. Pregnane X Receptor Mediates Sorafenib Resistance in Advanced Hepatocellular Carcinoma, Biochem. *Biophys Acta Gen Subj* (2018) 1862(4):1017–30. doi: 10.1016/j.bbagm.2018.01.001

22. Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 Inhibitor Betulin Enhances the Antitumor Effect of Sorafenib on Hepatocellular Carcinoma via Restricting Cellular Glycolytic Activity. *Cell Death Dis* (2019) 10(9):672. doi: 10.1038/s41419-019-1884-7

23. Feng YQ, Li BA, Feng F, Chen YS, Ren YX, Zhang H, et al. Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. *Onco Targets Ther* (2020) 13:7165–76. doi: 10.2147/OTT.S244474

24. Ma Y, Chai N, Jiang Q, Chang Z, Chai Y, Li X, et al. DNA Methylation Mediates the Hypermethylatation of the microRNA 3’-34a Promoter and Enhances the Resistance of Patient-Derived Pancreatic Cancer Cells to Molecular Targeting Agents. *Pharmacol Res* (2020) 165:105071. doi: 10.1016/j.phrs.2020.105071

25. Zhou W, Gao Y, Tong Y, Wu Q, Zhou Z, Yu L, Anlotinib Enhances the Antitumor Activity of Radiofrequency Ablation on Lung Squamous Cell Carcinoma. *Pharmacol Res* (2021) 164:105392. doi: 10.1016/j.phrs.2020.105392

26. Wang C, Ding S, Sun B, Shen L, Xiao L, Han Z, et al. Hsa-miR-4271 Targets ADAM-17 and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. *Oncotarget* (2019) 10(1):784. doi: 10.8419/1019-020-2273-y

27. Sheng et al. A20/HSP90 Complex on HCC
53. Jafari A, Rezaei-Tavirani M, Farhadhosseinabadi B, Taranejoo S, Zali H. HSP90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy. *Cancer Invest* (2020) 38(5):310–28. doi: 10.1080/07357907.2020.1752227

54. Nouri-Vaskeh M, Alizadeh L, Hajiajarzadek K, Mokhtarerazadhe A, Halimi M, Baradaranc B. The Role of HSP90 Molecular Chaperones in Hepatocellular Carcinoma. *J Cell Physiol* (2020) 235(12):9110–20. doi: 10.1002/jcp.29776

55. Chen F, Bao H, Xie H, Tian G, Jiang T. Heat Shock Protein Expression and Autophagy After Incomplete Thermal Ablation and Their Correlation. *Int J Hyperthermia* (2019) 36(1):195–103. doi: 10.1080/07357907.2018.1536285

56. Mohamady S, Ismail MI, Mogheith SM, Attia YM, Taylor SD. Discovery of 5-Aryl-3-Thiophen-2-Y1-H-Pyrazoles as a New Class of Hsp90 Inhibitors in Hepatocellular Carcinoma. *Bioorg Chem* (2020) 94:103433. doi: 10.1016/j.bioorg.2019.103433

57. Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovì S, Puleio R, et al. Targeting HSP90 With the Small Molecule Inhibitor AUY922 (Luminespib) as a Treatment Strategy Against Hepatocellular Carcinoma. *Int J Cancer* (2019) 144(10):2613–24. doi: 10.1002/ijc.31963

58. Zhao S, Li H, Jiang C, Ma T, Wu C, Huo Q, et al. 17-Demethoxy-HDA-1 Modulates Mitochondrial Stress Response and Longevity. *Nat Commun* (2020) 11(1):4639. doi: 10.1038/s41467-020-18501-w

59. Luo M, Meng Z, Moroishi T, Lin KC, Shen G, Mo F, et al. Heat Stress Activates YAP/TAZ to Induce the Heat Shock Transcriptome. *Nat Cell Biol* (2020) 22(12):1547–59. doi: 10.1038/s41556-020-00602-9

60. Seo HW, Seo JP, Jung G. Heat Shock Protein 70 and Heat Shock Protein 90 Synergistically Increase Hepatitis B Viral Capsid Assembly. *Biochem Biophys Res Commun* (2018) 503(4):2892–8. doi: 10.1016/j.bbrc.2018.08.065

61. Xu Q, Tu J, Dou C, Zhang J, Yang L, Liu X, et al. HSP90 Promotes Cell Glycolysis, Proliferation and Inhibits Apoptosis by Regulating PKM2. *J Cancer* (2020) 11(1):1467. doi: 10.1016/j.jca.2019.11.093

62. Dong L, Xue L, Zhang C, Li H, Cai Z, Guo R. HSP90 Interacts With HMGCR and Promotes the Progression of Hepatocellular Carcinoma. *Mol Med Rep* (2019) 19(1):324–32. doi: 10.3892/mmr.2019.6967

63. Song H, Wei Y, Sun J, Wang L, Wang Y, Liu B, et al. Akt-Targeted Therapy as a Promising Strategy to Overcome Drug Resistance in Breast Cancer - A Comprehensive Review From Chemotherapy to Akt-Targeted Therapy. *Mol Ther* (2019) 27(8):1697–709. doi: 10.1038/s41394-019-0270-x

64. Zhang C, Yang C, Feldman MJ, Wang H, Peng Y, Maggio DM, et al. Vorinostat Suppresses Hypoxia Signaling by Modulating Nuclear Translocation of Hypoxia Inducible Factor 1 Alpha. *Oncotarget* (2017) 8(34):56110–25. doi: 10.18632/oncotarget.18125

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shen, Sun, Chai, Jiang, Zhang, Li and Xin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.